Alligator Bioscience to Present ADC-1013 Intratumoral Clinical Phase I Study Results at SITC in November 2017
LUND, Sweden, Sept. 21, 2017 /PRNewswire/ --Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that results from a clinical phase I study of the drug candidate ADC-1013 (JNJ-64457107) will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, held from 8-12 November 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland, US.
Alligator Bioscience will give both an oral and poster presentation at the SITC conference with the title: "First-in-human study with intratumoral administration of a CD40 agonistic antibody: preliminary results with ADC-1013/JNJ-64457107 in advanced solid malignancies". The oral presentation will be held at Session Clinical Trials: New Agents, starting at 1:45 p.m. ET (7:45 p.m. CET) on November 10, 2017.
For further information about the program, please visit the conference web site:
For further information:
Cecilia Hofvander
Director Investor Relations & Communications
Phone +46-46-286-44-95
E-mail: cecilia.hofvander@alligatorbioscience.com.
This release contains information that Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CEST on 21 September 2017.
About ADC-1013
ADC-1013 is a drug candidate intended for immunotherapy of different types of cancer. Pre-clinical data have shown that the ADC-1013 antibody effectively activates T-cells, mediated through binding to the co-stimulatory receptor CD40 on dendritic cells. The increased T cell activation enables the immune system to attack the cancer. In addition, since some cancer cells express CD40 on the surface, ADC-1013 may act also through a secondary mechanism of action killing cancer cells directly.
In August 2015, Alligator licensed global development rights for ADC-1013 to Janssen Biotech Inc. In October 2016, Janssen Biotech, Inc. started a second phase I clinical study (ClinicalTrials: NCT02829099). That study is an intravenous dose escalation study with ADC-1013 (JNJ-64457107).
About the ADC-1013 clinical Phase I study
The study to be presented is a multicenter, open-label phase I study in patients with advanced solid tumors evaluating safety and tolerability, pharmacokinetics, immunogenicity, biomarker response and clinical response. The study is a dose-escalation study involving intratumoral and intravenous administration of ADC-1013 at five hospitals in Sweden, Denmark and the UK. The study was performed by Alligator and includes 24 patients and ten different tumor types. For further information, please visit www.clinicaltrials.gov; NCT02379741.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017, and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees. For more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017 |
Share this article